Literature DB >> 12622135

Intrasellar gangliocytomas associated with acromegaly.

Masamichi Kurosaki1, Wolfgang Saeger, Dieter K Lüdecke.   

Abstract

The present study was designed to investigate the immunohistochemical characteristics of gangliocytomas associated with growth hormone (GH)-secreting pituitary adenomas. In our surgical collection of 476 GH-secreting adenoma cases, we examined tumor tissue from 6 patients (1.3%). All 6 patients were women, ranging from 29 to 52 years (mean, 40.3 +/- 9.5 SD) of age. Among 470 patients with GH-secreting adenomas without gangliocytoma, there were 255 female and 215 male patients. The preponderance of female patients with gangliocytomas was striking. Histological examination of the resected specimens showed areas of ganglion cells and adenomatous cells. Ganglion cell lesions were stained positively for synaptophysin (4 of 4; 100%) and neurofilament (4 of 4; 100%) as well as GH-releasing hormone (5 of 6; 83.3%). Subtypes of GH cell adenomas included 4 cases of sparsely granulated type and 2 cases of mixed GH and prolactin (PRL) cell adenomas. Based on these findings, we hypothesized that the intrasellar gangliocytoma promoted the growth of the pituitary adenoma by chronic overstimulation from excess GH-releasing hormone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12622135     DOI: 10.1007/bf02478929

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  13 in total

1.  An intrasellar mixed gangliocytoma-adenoma including ependymal component, and review of the literature.

Authors:  Ping Xiao; Ling Xue; Jian-Jun Peng; Shi-Ting Feng; Bing Liao; Jian-Ming Wen
Journal:  BMJ Case Rep       Date:  2009-04-07

Review 2.  [New aspects of tumor pathology of the pituitary].

Authors:  W Saeger
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 3.  Infrasellar pituitary gangliocytoma causing Cushing's syndrome.

Authors:  Marie-Eve Domingue; Etienne Marbaix; Jean-Luc Do Rego; Vincent Col; Christian Raftopoulos; Thierry Duprez; Hubert Vaudry; Dominique Maiter
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

4.  Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma.

Authors:  M L Isidro; P Iglesias Díaz; X Matías-Guiu; F Cordido
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

5.  Multiple tumorous lesions of the pituitary gland.

Authors:  Jannik von Schöning; Jörg Flitsch; Dieter K Lüdecke; Rudolf Fahlbusch; Michael Buchfelder; Rolf Buslei; Ulrich J Knappe; Markus Bergmann; Walter J Schulz-Schaeffer; Jochen Herms; Markus Glatzel; Wolfgang Saeger
Journal:  Hormones (Athens)       Date:  2022-08-10       Impact factor: 3.419

6.  Pituitary adenoma with gangliocytic component: report of 5 cases with focus on immunoprofile of gangliocytic component.

Authors:  Serdar Balci; Arzu Saglam; Hakan Oruckaptan; Tomris Erbas; Figen Soylemezoglu
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

7.  Acromegaly associated with gangliocytoma.

Authors:  R K Crowley; Y Al-Derazi; K Lynch; D Rawluk; C J Thompson; M Farrell; A Agha
Journal:  Ir J Med Sci       Date:  2009-09-30       Impact factor: 1.568

8.  Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution.

Authors:  Robert Y Osamura; Noboru Egashira; Hanako Kajiya; Mao Takei; Maya Tobita; Takashi Miyakoshi; Chie Inomoto; Susumu Takekoshi; Akira Teramoto
Journal:  Acta Histochem Cytochem       Date:  2009-08-11       Impact factor: 1.938

9.  Ganglioglioma of the neurohypophysis.

Authors:  B W Scheithauer; A I Silva; J E Parisi; K Kovacs; E Horvath
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 10.  Collision sellar lesions: experience with eight cases and review of the literature.

Authors:  Maria Koutourousiou; George Kontogeorgos; Pieter Wesseling; Andre J Grotenhuis; Andreas Seretis
Journal:  Pituitary       Date:  2009-06-24       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.